TY - JOUR
T1 - Patterns of proton therapy use in pediatric cancer management in 2016
T2 - An international survey
AU - Journy, Neige
AU - Indelicato, Daniel J.
AU - Withrow, Diana R.
AU - Akimoto, Tetsuo
AU - Alapetite, Claire
AU - Araya, Masayuki
AU - Chang, Andrew
AU - Chang, John Han Chih
AU - Chon, Brian
AU - Confer, Michael E.
AU - Demizu, Yusuke
AU - Dendale, Rémi
AU - Doyen, Jérôme
AU - Ermoian, Ralph
AU - Gurtner, Kristin
AU - Hill-Kayser, Christine
AU - Iwata, Hiromitsu
AU - Kim, Joo Young
AU - Kwok, Young
AU - Laack, Nadia N.
AU - Lee, Choonsik
AU - Lim, Do Hoon
AU - Loredo, Lilia
AU - Mangona, Victor S.
AU - Mansur, David B.
AU - Murakami, Masao
AU - Murayama, Shigeyuki
AU - Ogino, Takashi
AU - Ondrová, Barbora
AU - Parikh, Rahul R.
AU - Paulino, Arnold C.
AU - Perkins, Stephanie
AU - Ramakrishna, Naren R.
AU - Richter, Ronald
AU - Rombi, Barbara
AU - Shibata, Satoshi
AU - Shimizu, Shinichi
AU - Timmermann, Beate
AU - Vern-Gross, Tamara
AU - Wang, Chiachien J.
AU - Weber, Damien C.
AU - Wilkinson, John Ben
AU - Witt Nyström, Petra
AU - Yock, Torunn I.
AU - Kleinerman, Ruth A.
AU - Berrington de Gonzalez, Amy
N1 - Publisher Copyright:
© 2018 Elsevier B.V.
PY - 2019/3
Y1 - 2019/3
N2 - Purpose: To facilitate the initiation of observational studies on late effects of proton therapy in pediatric patients, we report on current patterns of proton therapy use worldwide in patients aged less than 22 years. Materials & methods: Fifty-four proton centers treating pediatric patients in 2016 in 11 countries were invited to respond to a survey about the number of patients treated during that year by age group, intent of treatment, delivery technique and tumor types. Results: Among the 40 participating centers (participation rate: 74%), a total of 1,860 patients were treated in 2016 (North America: 1205, Europe: 432, Asia: 223). The numbers of patients per center ranged from 1 to 206 (median: 29). Twenty-four percent of the patients were <5 years of age, and 50% <10 years. More than 30 pediatric tumor types were identified, mainly treated with curative intent: 48% were CNS, 25% extra-cranial sarcomas, 7% neuroblastoma, and 5% hematopoietic tumors. About half of the patients were treated with pencil beam scanning. Treatment patterns were broadly similar across the three continents. Conclusion: To our knowledge, this survey provides the first worldwide assessment of proton therapy use for pediatric cancer management. Since previous estimates in the United States and Europe, CNS tumors remain the cancer types most commonly treated with protons in 2016. However, the proportion of extra-cranial tumors is growing worldwide. The typically low numbers of patients treated in each center indicate the need for international research collaborations to assess long-term outcomes of proton therapy in pediatric patients.
AB - Purpose: To facilitate the initiation of observational studies on late effects of proton therapy in pediatric patients, we report on current patterns of proton therapy use worldwide in patients aged less than 22 years. Materials & methods: Fifty-four proton centers treating pediatric patients in 2016 in 11 countries were invited to respond to a survey about the number of patients treated during that year by age group, intent of treatment, delivery technique and tumor types. Results: Among the 40 participating centers (participation rate: 74%), a total of 1,860 patients were treated in 2016 (North America: 1205, Europe: 432, Asia: 223). The numbers of patients per center ranged from 1 to 206 (median: 29). Twenty-four percent of the patients were <5 years of age, and 50% <10 years. More than 30 pediatric tumor types were identified, mainly treated with curative intent: 48% were CNS, 25% extra-cranial sarcomas, 7% neuroblastoma, and 5% hematopoietic tumors. About half of the patients were treated with pencil beam scanning. Treatment patterns were broadly similar across the three continents. Conclusion: To our knowledge, this survey provides the first worldwide assessment of proton therapy use for pediatric cancer management. Since previous estimates in the United States and Europe, CNS tumors remain the cancer types most commonly treated with protons in 2016. However, the proportion of extra-cranial tumors is growing worldwide. The typically low numbers of patients treated in each center indicate the need for international research collaborations to assess long-term outcomes of proton therapy in pediatric patients.
KW - Patterns of care
KW - Pediatrics
KW - Proton therapy
KW - Survey
UR - http://www.scopus.com/inward/record.url?scp=85055966908&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2018.10.022
DO - 10.1016/j.radonc.2018.10.022
M3 - Article
C2 - 30414759
AN - SCOPUS:85055966908
SN - 0167-8140
VL - 132
SP - 155
EP - 161
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
ER -